18:29 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

Strongbridge Biopharma plc (NASDAQ:SBBP) said Recorlev levoketoconazole met the primary and secondary endpoints in the Phase III SONICS trial to treat endogenous Cushing syndrome. On the 94-patient trial's primary endpoint, 30% of patients achieved normalization of...
17:57 , Jul 20, 2018 |  BC Week In Review  |  Company News

Takeda, Ovid expand TAK-935 collaboration with three new trials

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Ovid Therapeutics Inc. (NASDAQ:OVID) expanded their collaboration for TAK-935 (OV935) to include three new trials in pediatric populations, including in two additional rare epilepsy syndromes. The partners expect to...
16:53 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

FDA approves J&J's Symtuza for HIV-1 infection in adults

FDA approved Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide from Johnson & Johnson (NYSE:JNJ) to treat HIV-1 infection in adults who have not previously received antiretroviral therapy (ART) or who have HIV-1 RNA levels of less than 50 copies/mL...
17:47 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 124 genomic loci could help predict the risk of myopia and other ocular refractive errors. Genome-wide association studies (GWAS) in 255,925 individuals identified associations between ocular refractive errors including myopia and...
18:19 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS In vitro and cell culture studies identified an allophenylnorstatine-tetrahydrofuranylglycine conjugate-based inhibitor of HIV protease that could help treat protease inhibitor-resistant HIV infection. Chemical synthesis and in vitro activity assays of allophenylnorstatine-tetrahydrofuranylglycine conjugate analogs yielded...
18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro, cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based signaling assays...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing fibroblast...
22:43 , Apr 10, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Biosynthesis A liver microsome-based biosynthesis method could be used to generate multiple analogs of drug compounds. The method involves four steps: generating preparations of liver microsomes from eight mammalian species (mouse, rat, hamster, guinea pig,...
18:27 , Apr 5, 2018 |  BC Innovations  |  Emerging Company Profile

Stoking protein production

Stoke Therapeutics Inc. is developing ASOs to boost normal protein expression as disease-modifying therapies for autosomal-dominant diseases that are not amenable to recombinant protein or gene therapies. Co-founders Adrian Krainer and Isabel Aznarez previously discovered cell...
00:54 , Mar 10, 2018 |  BioCentury  |  Product Development

Defining progress

Erleada apalutamide’s landmark approval established a new primary endpoint in prostate cancer that shortens the time it takes to run the trials by up to five years, and paves the way for treating disease before...